Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. InventisBio Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.
InventisBio Co's long-term debt to total assets ratio
declined
from Mar. 2025 (0.01) to Mar. 2026 (0.01).
It may suggest that InventisBio Co is progressively becoming less dependent on debt to grow their business.
InventisBio Co (SHSE:688382) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
InventisBio Co LT-Debt-to-Total-Asset Related Terms
InventisBio Co LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for InventisBio Co's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InventisBio Co (SHSE:688382) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on InventisBio Co and its competitors.
Is InventisBio Co's LT-Debt-to-Total-Asset too high?
InventisBio Co's current LT-Debt-to-Total-Asset is 0.01. Overall, InventisBio Co has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InventisBio Co's LT-Debt-to-Total-Asset compare to VRTX and REGN?
InventisBio Co's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on InventisBio Co and its competitors. InventisBio Co's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InventisBio Co stock overvalued right now?
Based on GuruFocus' analysis, InventisBio Co (SHSE:688382) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥10.07, compared to a current price of ¥25.99 — trading 158.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. InventisBio Co's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For InventisBio Co (SHSE:688382), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InventisBio Co (SHSE:688382) Overvalued in 2026?
Based on GuruFocus' analysis, InventisBio Co stock appears to be overvalued.
The current stock price of ¥25.99 is trading 158.1% above its estimated GF Value™ of ¥10.07.
GuruFocus considers InventisBio Co to be Significantly Overvalued.
Key valuation signals for SHSE:688382:
LT-Debt-to-Total-Asset: 0.01
GF Value™: ¥10.07 vs. price of ¥25.99 (158.1% above fair value)
No single metric tells the full story. See the SHSE:688382 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
29GF Score
Get the complete analysis for SHSE:688382
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688382 has been successfully added to your 
